Dual variable domain immunoglobulins and uses thereof

A method for treating a subject for a disease or a disorder, comprising administering to the subject a binding protein comprising first and second polypeptide chains, each independently comprising VD1-(X1)n-VD2-C—(X2)n, wherein

• VD1 is a first variable domain;
• VD2 is a second variable domain;
• C is a constant domain;
• X1 is a linker;
• X2 is an Fc region;
• n is 0 or 1;
• wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site, wherein the binding protein is capable of binding IL-17 and TNFα, and wherein the variable domains that form a functional target binding site for IL-17 comprise CDRs 1-3 from SEQ ID NO:
• 40 and CDRs 1-3 from SEQ ID NO:
• 41.

A pharmaceutical composition comprising a binding protein, wherein the binding protein comprises first and second polypeptide chains, each independently comprising VD1-(X1)n-VD2-C—(X2)n, wherein

• VD1 is a first variable domain;
• VD2 is a second variable domain;
• C is a constant domain;
• X1 is a linker;
• X2 is an Fc region;
• n is 0 or 1;
• wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site, wherein the binding protein is capable of binding IL-17 and TNFα, and wherein the variable domains that form a functional target binding site for IL-17 comprise CDRs 1-3 from SEQ ID NO:
• 40 and CDRs 1-3 from SEQ ID NO:
• 41.

An isolated nucleic acid encoding a binding protein amino acid sequence, wherein the binding protein comprises first and second polypeptide chains, each independently comprising VD1-(X1)n-VD2-C—(X2)n, wherein

• VD1 is a first variable domain;
• VD2 is a second variable domain;
• C is a constant domain;
• X1 is a linker;
• X2 is an Fc region;
• n is 0 or 1;
• wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site, wherein the binding protein is capable of binding IL-17 and TNFα, and wherein the variable domains that form a functional target binding site for IL-17 comprise CDRs 1-3 from SEQ ID NO:
• 40 and CDRs 1-3 from SEQ ID NO:
• 41.

A method of determining the presence, amount, or concentration of IL-17 and/or TNFα in a test sample by an immunoassay,

• wherein the immunoassay comprises contacting the test sample with at least one binding protein and at least one detectable label, and
• wherein the at least one binding protein comprises first and second polypeptide chains, each independently comprising VD1-(X1)n-VD2-C—(X2)n, wherein
• VD1 is a first variable domain;
• VD2 is a second variable domain;
• C is a constant domain;
• X1 is a linker;
• X2 is an Fc region;
• n is 0 or 1;
• wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site, wherein the binding protein is capable of binding IL-17 and TNFα, and wherein the variable domains that form a functional target binding site for IL-17 comprise CDRs 1-3 from SEQ ID NO:
• 40 and CDRs 1-3 from SEQ ID NO:
• 41.

A kit for assaying a test sample for the presence, amount, or concentration of IL-17 and/or TNFα, the kit comprising

• (a) instructions for assaying the test sample for IL-17 and/or TNFα and
• (b) at least one binding protein comprising first and second polypeptide chains, each independently comprising VD1-(X1)n-VD2-C—(X2)n, wherein
• VD1 is a first variable domain;
• VD2 is a second variable domain;
• C is a constant domain;
• X1 is a linker;
• X2 is an Fc region;
• n is 0 or 1;
• wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site, wherein the binding protein is capable of binding IL-17 and TNFα, and wherein the variable domains that form a functional target binding site for IL-17 comprise CDRs 1-3 from SEQ ID NO:
• 40 and CDRs 1-3 from SEQ ID NO:
• 41.